UPDATE ON THE THERAPEUTIC APPROACH OF NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW

Abstract

This systematic review aims to discuss and compare the drug therapeutic update of Non-Alcoholic Fatty Liver Disease (NAFLD) and evaluate its benefits when compared to current treatment guidelines. The methodological part is formed by the Cochrane Library, the National Library of Medicine, the Virtual Health Library and the Directory of Open Access Journals, which were the databases used to form the bibliographic compilation of this literature review. The descriptors used were “steatohepatitis”, “nonalcoholic fatty liver disease” and “drug therapy”. Inclusion criteria were articles from clinical trials, randomized or non-randomized, case-control studies, cohort study, free access, published in English, Portuguese, Spanish and in the period from 2017 to 2022. Of the 13 articles addressed, three articles addressed Empagliflozin, 2 articles addressed Semaglutide and Tofogliflozin, which is associated with Glimepiride and Pioglitazone. 1 article reports Liraglutide, Canagliflozin, Sitagliptin, Pemafibrate and the associations of Dapagliflozin+Saxagliptin and Ezetimibe+Rosuvastatin. Thus, the three drugs that are empagliflozin, semaglutide and tofogliflozin, along with the drugs glimepiride and pioglitazone, are listed as the main treatments for NAFLD, with the average age of study participants being 45 years.